Live Breaking News & Updates on Clinical Trials Career Development Program

Stay updated with breaking news from Clinical trials career development program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Rapt slapped with phase II hold on CCR4 prospect

On the verge of top-line data from its phase IIb trial with oral small-molecule CC chemokine receptor 4 (CCR4) antagonist zelnecirnon in atopic dermatitis (AD), due around the middle of this year, Rapt Therapeutics Inc. said the U.S. FDA has imposed a clinical hold on that study with the otherwise promising drug, also known as RPT-193, in AD as well as the phase IIa trial with the same compound in asthma. ....

Rapt Therapeutics Inc , Rapt Therapeutics , Rapt Therapeutics Inc , Rpt 193 , Atopic Dermatitis , Clinical Hold , Cc Chemokine Receptor 4 Antagonist , Liver Failure ,

Live by the SORD: Applied Therapeutics looks to rare disease NDA

Based on positive phase III study data, Applied Therapeutics Inc. plans to take its CNS-penetrant aldose reductase inhibitor to the U.S. FDA to talk about an NDA for treating the rare disease sorbitol dehydrogenase (SORD) deficiency. SORD, a hereditary axonal neuropathy created by sorbitol dehydrogenase gene mutations, affects about 3,300 people in the U.S. and about 4,000 in Europe, according to Applied Therapeutics. ....

Therapeutics Inc , Applied Therapeutics , Applied Therapeutics Inc , At 007 , Sorbitol Dehydrogenase Deficiency , Rare Disease , Neurology Psychiatric , Charcot Marie Tooth Disease , Distal Hereditary Motor Neuropathy ,

Global eClinical Solutions Market Outlook 2024-2028: Industry to Reach $13.48 Billion by 2028, Driven by Interoperability and Telehealth Adoption

Dublin, Feb. 14, 2024 (GLOBE NEWSWIRE) The "eClinical Solutions Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The global eClinical solutions market size has grown rapidly in recent years. It will grow from $7.59 billion in 2023 to $8.47 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth observed in the historical period can be attributed to several key factors, including the expansion of healthcare digitalization, the widesprea ....

South Korea , United Kingdom , United States , Development Phase , Bioclinicia Inc , Maxisit Inc , Anju Software Inc , Medidata Solutions Inc , Studykik Inc , Acceliant Inc , Omnicomm Systems Inc , Clinical Research , Ai Inc , Medlink Inc , Cinven Ltd , Datatrak International Inc , Key Companies , Clinical Solutions , System Inc , Whealthcare Solutions Inc , Watson Health , Parexel International Corporation , Mednet Solutions , Saama Technologies Inc , Academic Research Institutions , Biopharmaceutical Companies ,